Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.43 |
| ▸ | WNT1 | P04628 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777065 | 0.90 | GSK3B (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL17777084 | 0.88 | GSK3B (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL17770095 | 0.88 | GSK3B (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19714482 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19714226 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19736468 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19714395 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19735189 | 0.87 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19714022 | 0.87 | DYRK1A (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19713766 | 0.86 | RPS6KA3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | claimed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885WNT1 3504/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885WNT1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.